Collagenous colitis: Requirement for high-dose budesonide as maintenance treatment
- 1 September 2017
- journal article
- research article
- Published by Elsevier in Digestive and Liver Disease
- Vol. 49 (9) , 973-977
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Current concepts on microscopic colitis: evidence‐based statements and recommendations of the Spanish Microscopic Colitis GroupAlimentary Pharmacology & Therapeutics, 2015
- Azathioprine and mercaptopurine in the management of patients with chronic, active microscopic colitisAlimentary Pharmacology & Therapeutics, 2013
- Microscopic colitis: Current status, present and future challengesJournal of Crohn's and Colitis, 2012
- Health-related quality of life is impaired in active collagenous colitisDigestive and Liver Disease, 2011
- Fracture Risk Associated with Different Types of Oral Corticosteroids and Effect of Termination of Corticosteroids on the Risk of FracturesCalcified Tissue International, 2008
- Pharmacokinetics and bone effects of budesonide in primary biliary cirrhosisAlimentary Pharmacology & Therapeutics, 2006
- Bone mineral density in Crohn's disease: a longitudinal study of budesonide, prednisone, and nonsteroid therapyAmerican Journal of Gastroenterology, 2002
- Use of Azathioprine or 6-mercaptopurine for treatment of steroid-dependent lymphocytic and collagenous colitisAmerican Journal of Gastroenterology, 2001
- Treatment of refractory microscopic colitis with azathioprine and 6-mercaptopurineGastroenterology, 2001
- Non-steroidal anti-inflammatory drugs as a possible cause of collagenous colitis: a case-control study.Gut, 1992